| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2011-05-05 | Selvita (Poland) | PLN 14,85 million ($ 5.5 million - € 3.74 million) | private placement | Cancer - Oncology | Private placement | |
| 2011-05-03 | MdxHealth (Belgium) | $ 1.1 million (€ 0.74 million) | grant | EuroTransBio (European Commission initiative to foster cross border research & development between companies and academia working in the biotech industry) (EU) | Cancer - Oncology | Grant |
| 2011-05-03 | Delenex Therapeutics (Switzerland) | CHF 30.2 million (€23.5 million) | Series A venture equity investment round | Novo Ventures (Denmark) - SV Life Sciences (UK - USA) - HBM BioCapital (Cayman Islands) - HBM BioVentures (Cayman Islands) - BioMedInvest (Switzerland) - VI Partners (Switzerland) | CNS diseases - Dermatological diseases - Inflammatory diseases | Fundraising |
| 2011-05-03 | ProFibrix (The Netherlands ) | €15 million ($22 million) | series B follow-on financing and government credit | Vesalius Biocapital (Luxembourg) - INKEF Capital | Regenerative medicine - Hemostasis | Fundraising |
| 2011-04-27 | Multiplicom (Belgium) | € 2.0 million | Series A funding round | Gimv (Belgium) VIB (Belgium) University of Antwerp (Belgium) | Cancer - Oncology - Genetic diseases | Fundraising |
| 2011-04-19 | Curetis (Germany) | € 0.5 million | grant | Federal Ministry of Economics and Technology (Germany) | Infectious diseases | Grant |
| 2011-04-19 | Circassia (UK) | £60 million (€66.8 million) | financing round | Imperial Innovations (UK) Invesco Perpetual (UK) | Allergic diseases - Inflammatory diseases - Respiratory diseases | Fundraising |
| 2011-04-19 | Circassia (UK) | £60 Million (€67 million - $98 Million) | fundraising | Imperial Innovations (UK) - other existing shareholders, including Invesco Perpetual | Allergic diseases - Inflammatory diseases - Respiratory diseases | Fundraising |
| 2011-04-14 | ArcticZymes (Norway) | MNOK 7.2 (€ 0.9 million) | grant | Research Council of Norway | Technology - Services | Grant |
| 2011-04-14 | Vironova (Sweden) | €1,72 million | grant | European Eurostars Programme (EU) | Infectious diseases | Grant |
| 2011-04-13 | mondoBIOTECH (Switzerland) | CHF 8 million (€ 6.2 million) | share capital increase | shareholders | Rare diseases | Capital increase |
| 2011-04-12 | AB Science (France) | € 7,539,400 | bond loan agreement | shareholders | Cancer - Oncology - Neurodegenerative diseases | Establishment of a new subsidiary in the EU |
| 2011-04-12 | Adenovir Pharma (Sweden) | SEK 10.7 million (€ 1.17 million) | rights issue | BWG Holding - P.U.L.S. AB (Sweden) - Länsförsäkringar Skåne (Sweden) - Sparbanksstiftelsen Skånes Riskkapitalstiftelse (Sweden) - Augmenta | Infectious diseases - Ophtalmological diseases | Private placement |
| 2011-04-11 | Scil Proteins (Germany) | €700K | grant | Investitionsbank Sachsen Anhalt (Germany) | Cancer - Oncology | Grant |
| 2011-04-09 | Algipharma (Norway) | grant | Cystic Fibrosis Foundation Therapeutics (USA) | Rare diseases - Genetic diseases | Grant | |
| 2011-04-05 | Cellectis (France) | €12 million | capital increase | Caisse des dépôts (France) | Technology - Services | Capital increase |
| 2011-04-05 | MDxHealth (Belgium) | € 8.2 Million | private placement of new shares | Cancer - Oncology | Private placement | |
| 2011-04-05 | PathoQuest (France) | €2 million | series A financing round | Kurma Biofund (France) | Infectious diseases | Fundraising |
| 2011-04-01 | Thrombogenics (Belgium) | € 173 340 | capital increase arising from employee warrant exercises | employees | Ophtalmological diseases | Capital increase |
| 2011-04-01 | Neovacs (France) | € 2.25 million | private placement | Debioinnovation (Switzerland) - OTC Asset Management (France) - Truffle Capital (France) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Private placement |
